‘What can we do with this, other than watch it multiply?': Expert warns over lab-grown bat viruses as 20 new strains discovered
The findings, published in the journal PLOS Pathogens, have prompted fresh warnings over future spillover threats to humans and livestock - but not all the concern is about the viruses themselves.
Australian infectious diseases expert Professor Peter Collignon has raised concerns over the way such viruses are being studied, warning that lab-based research may give dangerous pathogens a 'head start'.
'It's a concern that these viruses are often grown in laboratories in human or monkey cell types, and you have to ask yourself - what can we do with this other than watch it multiply?' Professor Collignon told SkyNews.com.au.
The viruses were uncovered after researchers examined the kidneys of 142 fruit bats from the Yunnan province, a biodiversity hotspot bordering Myanmar and Laos.
Unlike most studies that analyse bat droppings, this research focused on organ tissues - uncovering a trove of previously unknown viruses and revealing a rarely studied viral reservoir.
Two of the viruses, dubbed Yunnan bat Henipavirus 1 and 2, are particularly concerning due to their genetic similarities to Hendra and Nipah - pathogens known for causing fatal outbreaks in humans and animals, with fatality rates as high as 80 per cent.
The viruses, which can spread via bat urine, were found in animals roosting near orchards and villages - raising concerns about possible transmission to livestock or people via contaminated fruit or surfaces.
The Hendra virus, first detected in Brisbane in 1994, has caused the deaths of four people and dozens of horses in Australia.
With flying fox populations increasingly seen in peri-urban and agricultural areas, the environmental conditions in Yunnan are drawing direct comparisons to those in parts of Australia.
But as more of these viruses are found, debate is growing over whether the act of studying them - particularly in labs - could pose its own risks.
'With what's happening at the moment by growing these viruses in a lab in human cell lines, it's only giving the virus a head start in an ability to infect people rather than just bats,' Mr Collignon said.
'We get information about it, which is obviously important, but there's usually no other benefit - except maybe the people carrying out the study getting extra grants.'
He said the value of identifying these viruses is often overstated, arguing that knowing about Covid-19 in bats before the pandemic made little difference to prevention.
'We knew about coronaviruses including those from bats, long before the pandemic happened, but really, how does that help? It didn't really,' he said.
'We likely only know about one per cent of the viruses out there. Knowing about them doesn't always mean we can stop them.'
Mr Collignon also questioned public messaging which linked bat virus studies to current vaccine campaigns, calling it misplaced and potentially misleading.
'Like coming out now and trying to prevent this virus harming people by telling people to get the current Covid vaccine. It just won't help, as it's very unlikely we will get cross protection' he said.
'It's misleading information.'
Ecologists, meanwhile, say the real issue is habitat destruction - not laboratory research.
Deforestation, habitat fragmentation, and food shortages are forcing bats to forage closer to human environments, which has been linked to increased risk of zoonotic spillover in both Asia and Australia.
A 2023 study of Hendra outbreaks in horses found a strong link between bat food scarcity and virus transmission.
As natural food sources decline, bats have been increasingly observed feeding in orchards and farms, heightening the risk of contact.
Many ecologists argue conservation - not culling - is key to reducing the risk of disease emergence.
Maintaining native food sources and restoring natural habitats can help bats stay away from farmland, they say, reducing spillover risk at the source.
While there's no evidence the newly discovered viruses have yet infected humans, the discovery highlights how little is still known about the microbial world carried by wildlife - especially in biodiversity hotspots.
Mr Collignon stressed the importance of balancing research with caution.
'There's always going to be that natural concern between bats, the viruses they carry and the risk to the public,' he said.
'But giving [a virus] a head start as part of research program that grows these viruses in human cell lines is not good.'
Experts are calling for a more ecological approach to disease prevention - one that treats habitat protection as frontline public health.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Advertiser
5 hours ago
- The Advertiser
Pascal's fame stretches Down Under for Fantastic Four
Stars of the upcoming Fantastic Four film have graced Australian shores for its local launch. Actor Pedro Pascal, who plays the stretchy superhero Reed Richards, headlined the promotional event in Sydney for Fantastic Four: First Steps - the third silver-screen incarnation of the comic-book series and first in the Marvel Cinematic Universe. Pascal, star of The Mandalorian and The Last of Us, makes his first appearance leading a superhero movie as his star continues to rise. The first Fantastic Four film in 2005 and its 2007 sequel were commercially successful but received a mixed critical reception, before a 2015 reboot panned by audiences and critics alike. This latest iteration, from TV mini-series WandaVision director Matt Shakman, stars Pascal as Richards - also known as Mister Fantastic - who can stretch any part of his body at will to superhuman lengths. The others in the titular quartet stepping out in Sydney are Vanessa Kirby (Sue Storm/Invisible Woman), Ebon Moss-Bachrach (Ben Grimm/The Thing) and Joseph Quinn (Johnny Storm/Human Torch). Kirby shares an interesting trait with her on-screen persona, with both actor and character sporting baby bumps. In the film, the Four "must defend earth from a ravenous space god called Galactus (Ralph Ineson) and his enigmatic Herald, Silver Surfer (Julia Garner)". The action happens on parallel planet Earth-828 and features elements of 1960s culture and futuristic technology. The return of the Fantastic Four to the silver screen will lead into the 2026 release of the next Avengers film, Avengers: Doomsday, the film's producer and Marvel Studios head Kevin Feige said in June. Fantastic Four: First Steps will be released in Australian cinemas on July 24. Stars of the upcoming Fantastic Four film have graced Australian shores for its local launch. Actor Pedro Pascal, who plays the stretchy superhero Reed Richards, headlined the promotional event in Sydney for Fantastic Four: First Steps - the third silver-screen incarnation of the comic-book series and first in the Marvel Cinematic Universe. Pascal, star of The Mandalorian and The Last of Us, makes his first appearance leading a superhero movie as his star continues to rise. The first Fantastic Four film in 2005 and its 2007 sequel were commercially successful but received a mixed critical reception, before a 2015 reboot panned by audiences and critics alike. This latest iteration, from TV mini-series WandaVision director Matt Shakman, stars Pascal as Richards - also known as Mister Fantastic - who can stretch any part of his body at will to superhuman lengths. The others in the titular quartet stepping out in Sydney are Vanessa Kirby (Sue Storm/Invisible Woman), Ebon Moss-Bachrach (Ben Grimm/The Thing) and Joseph Quinn (Johnny Storm/Human Torch). Kirby shares an interesting trait with her on-screen persona, with both actor and character sporting baby bumps. In the film, the Four "must defend earth from a ravenous space god called Galactus (Ralph Ineson) and his enigmatic Herald, Silver Surfer (Julia Garner)". The action happens on parallel planet Earth-828 and features elements of 1960s culture and futuristic technology. The return of the Fantastic Four to the silver screen will lead into the 2026 release of the next Avengers film, Avengers: Doomsday, the film's producer and Marvel Studios head Kevin Feige said in June. Fantastic Four: First Steps will be released in Australian cinemas on July 24. Stars of the upcoming Fantastic Four film have graced Australian shores for its local launch. Actor Pedro Pascal, who plays the stretchy superhero Reed Richards, headlined the promotional event in Sydney for Fantastic Four: First Steps - the third silver-screen incarnation of the comic-book series and first in the Marvel Cinematic Universe. Pascal, star of The Mandalorian and The Last of Us, makes his first appearance leading a superhero movie as his star continues to rise. The first Fantastic Four film in 2005 and its 2007 sequel were commercially successful but received a mixed critical reception, before a 2015 reboot panned by audiences and critics alike. This latest iteration, from TV mini-series WandaVision director Matt Shakman, stars Pascal as Richards - also known as Mister Fantastic - who can stretch any part of his body at will to superhuman lengths. The others in the titular quartet stepping out in Sydney are Vanessa Kirby (Sue Storm/Invisible Woman), Ebon Moss-Bachrach (Ben Grimm/The Thing) and Joseph Quinn (Johnny Storm/Human Torch). Kirby shares an interesting trait with her on-screen persona, with both actor and character sporting baby bumps. In the film, the Four "must defend earth from a ravenous space god called Galactus (Ralph Ineson) and his enigmatic Herald, Silver Surfer (Julia Garner)". The action happens on parallel planet Earth-828 and features elements of 1960s culture and futuristic technology. The return of the Fantastic Four to the silver screen will lead into the 2026 release of the next Avengers film, Avengers: Doomsday, the film's producer and Marvel Studios head Kevin Feige said in June. Fantastic Four: First Steps will be released in Australian cinemas on July 24. Stars of the upcoming Fantastic Four film have graced Australian shores for its local launch. Actor Pedro Pascal, who plays the stretchy superhero Reed Richards, headlined the promotional event in Sydney for Fantastic Four: First Steps - the third silver-screen incarnation of the comic-book series and first in the Marvel Cinematic Universe. Pascal, star of The Mandalorian and The Last of Us, makes his first appearance leading a superhero movie as his star continues to rise. The first Fantastic Four film in 2005 and its 2007 sequel were commercially successful but received a mixed critical reception, before a 2015 reboot panned by audiences and critics alike. This latest iteration, from TV mini-series WandaVision director Matt Shakman, stars Pascal as Richards - also known as Mister Fantastic - who can stretch any part of his body at will to superhuman lengths. The others in the titular quartet stepping out in Sydney are Vanessa Kirby (Sue Storm/Invisible Woman), Ebon Moss-Bachrach (Ben Grimm/The Thing) and Joseph Quinn (Johnny Storm/Human Torch). Kirby shares an interesting trait with her on-screen persona, with both actor and character sporting baby bumps. In the film, the Four "must defend earth from a ravenous space god called Galactus (Ralph Ineson) and his enigmatic Herald, Silver Surfer (Julia Garner)". The action happens on parallel planet Earth-828 and features elements of 1960s culture and futuristic technology. The return of the Fantastic Four to the silver screen will lead into the 2026 release of the next Avengers film, Avengers: Doomsday, the film's producer and Marvel Studios head Kevin Feige said in June. Fantastic Four: First Steps will be released in Australian cinemas on July 24.
Sydney Morning Herald
8 hours ago
- Sydney Morning Herald
The supermarket ‘antidepressant' in your spice rack
Probiotics and vitamin D were more likely than a placebo to reduce depressive symptoms, while most studies found no effects for Omega-3, according to lead author Rachael Frost, a senior lecturer at Liverpool John Moores University. 'However, St John's Wort and saffron more often showed effects compared to placebo, and similar results to prescription antidepressants,' Frost wrote in an accompanying editorial in Frontiers of Pharmacology. Frost, we should note, is a herbal medicine practitioner herself; the first of many caveats we'll cover on this study. It's not surprising St John's Wort showed a strong effect. A Cochrane review, the gold-standard for scientific evidence, found the flower extract could treat symptoms of depression as effectively as antidepressants back in 2008. Ian Hickie, professor of psychiatry and co-director of health and policy at the University of Sydney's Brain and Mind Centre, said St John's Wort is known to be pharmacologically similar to a weak SSRI (selective serotonin reuptake inhibitor) antidepressant medication. 'It should be seen as a 'medicine' and not simply a natural product,' he says. Hickie noted that many of the other natural interventions weighed up in the review were tested on subclinical depression, not the severe illness conventional antidepressants are aimed at, which is important to consider when interpreting the results. The review also didn't analyse the statistical power of each trial's results, which most modern meta-analyses do, and instead simply collated the number of positive and negative experiments on each substance. That doesn't take us far, particularly because most of the trials included in the review had small sample sizes. So where does that leave us with the claim that saffron, alongside St John's Wort, could be as potent as a prescription antidepressant? A narrow evidence base Eighteen studies on saffron were included in the review. Most found the substance improved people's mood and alleviated depression at least as well as conventional medication. But, reading the studies one by one, something caught my eye: at least half were co-authored by the same researcher. Further, all but one of the studies emerged from a small group of research organisations in Iran. That's not surprising; Iran produces 90 per cent of the world's saffron, so naturally the country's scientists would lead experiments on its therapeutic potential. What it does show, however, is that the experimental landscape for saffron is very concentrated. To be confident that a certain new drug or intervention works, ideally, you want labs across many countries running experiments with a range of settings and participants of different ethnicities. It's safe to say the evidence base, as it stands, is narrow. The one study referenced in the paper completed outside of Iran was an Australian one led by Dr Adrian Lopresti, which found saffron extract could help reduce depressive symptoms in people already taking a pharmaceutical antidepressant. Lopresti, who's the managing director of Clinical Trials Australia, also just published a new paper that marks the largest study to date on saffron and mood, with 202 participants. The trial found 72.3 per cent of participants with depressive symptoms (not clinical depression) taking saffron extract significantly improved compared to 54.3 per cent of people on a placebo. Scientists believe saffron could address chemical issues associated with depression, which include problems with neurotransmitters, high inflammatory blood markers, and low levels of antioxidants. 'Saffron is an anti-inflammatory, it's an antioxidant, and it impacts on neurotransmitters too, so it probably works through those different mechanisms,' Lopresti says. Fine print and industry funding But these Australian studies, too, come with a crucial caveat: they were funded by a biotech company that sells saffron supplements. 'I think what you've got to really do is not hedge your bets on just one single study,' Lopresti says when I ask how people should interpret studies funded by industry. 'Has it been replicated across the world with different research organisations?' Loading Jerome Sarris, professor of integrative mental health at the NICM medical research institute, said it's important to note potential conflicts of interest. But they can be managed in placebo-controlled, double-blind studies – where participants and experimenters don't know who's on the placebo – as long as data is analysed independently of industry. 'Of course, read the fine print, look at the conflict of interest and weigh that up in your own mind. But I would also say universities are pretty good in terms of having safeguards around conflict of interest management,' he says. People considering supplements for mood or mental illness should seek professional health advice. Herbs and other supplements can interact with other medications. St John's Wort, for example, can lead to a potentially life-threatening increase in serotonin when combined with some antidepressants.
The Age
8 hours ago
- The Age
The supermarket ‘antidepressant' in your spice rack
Probiotics and vitamin D were more likely than a placebo to reduce depressive symptoms, while most studies found no effects for Omega-3, according to lead author Rachael Frost, a senior lecturer at Liverpool John Moores University. 'However, St John's Wort and saffron more often showed effects compared to placebo, and similar results to prescription antidepressants,' Frost wrote in an accompanying editorial in Frontiers of Pharmacology. Frost, we should note, is a herbal medicine practitioner herself; the first of many caveats we'll cover on this study. It's not surprising St John's Wort showed a strong effect. A Cochrane review, the gold-standard for scientific evidence, found the flower extract could treat symptoms of depression as effectively as antidepressants back in 2008. Ian Hickie, professor of psychiatry and co-director of health and policy at the University of Sydney's Brain and Mind Centre, said St John's Wort is known to be pharmacologically similar to a weak SSRI (selective serotonin reuptake inhibitor) antidepressant medication. 'It should be seen as a 'medicine' and not simply a natural product,' he says. Hickie noted that many of the other natural interventions weighed up in the review were tested on subclinical depression, not the severe illness conventional antidepressants are aimed at, which is important to consider when interpreting the results. The review also didn't analyse the statistical power of each trial's results, which most modern meta-analyses do, and instead simply collated the number of positive and negative experiments on each substance. That doesn't take us far, particularly because most of the trials included in the review had small sample sizes. So where does that leave us with the claim that saffron, alongside St John's Wort, could be as potent as a prescription antidepressant? A narrow evidence base Eighteen studies on saffron were included in the review. Most found the substance improved people's mood and alleviated depression at least as well as conventional medication. But, reading the studies one by one, something caught my eye: at least half were co-authored by the same researcher. Further, all but one of the studies emerged from a small group of research organisations in Iran. That's not surprising; Iran produces 90 per cent of the world's saffron, so naturally the country's scientists would lead experiments on its therapeutic potential. What it does show, however, is that the experimental landscape for saffron is very concentrated. To be confident that a certain new drug or intervention works, ideally, you want labs across many countries running experiments with a range of settings and participants of different ethnicities. It's safe to say the evidence base, as it stands, is narrow. The one study referenced in the paper completed outside of Iran was an Australian one led by Dr Adrian Lopresti, which found saffron extract could help reduce depressive symptoms in people already taking a pharmaceutical antidepressant. Lopresti, who's the managing director of Clinical Trials Australia, also just published a new paper that marks the largest study to date on saffron and mood, with 202 participants. The trial found 72.3 per cent of participants with depressive symptoms (not clinical depression) taking saffron extract significantly improved compared to 54.3 per cent of people on a placebo. Scientists believe saffron could address chemical issues associated with depression, which include problems with neurotransmitters, high inflammatory blood markers, and low levels of antioxidants. 'Saffron is an anti-inflammatory, it's an antioxidant, and it impacts on neurotransmitters too, so it probably works through those different mechanisms,' Lopresti says. Fine print and industry funding But these Australian studies, too, come with a crucial caveat: they were funded by a biotech company that sells saffron supplements. 'I think what you've got to really do is not hedge your bets on just one single study,' Lopresti says when I ask how people should interpret studies funded by industry. 'Has it been replicated across the world with different research organisations?' Loading Jerome Sarris, professor of integrative mental health at the NICM medical research institute, said it's important to note potential conflicts of interest. But they can be managed in placebo-controlled, double-blind studies – where participants and experimenters don't know who's on the placebo – as long as data is analysed independently of industry. 'Of course, read the fine print, look at the conflict of interest and weigh that up in your own mind. But I would also say universities are pretty good in terms of having safeguards around conflict of interest management,' he says. People considering supplements for mood or mental illness should seek professional health advice. Herbs and other supplements can interact with other medications. St John's Wort, for example, can lead to a potentially life-threatening increase in serotonin when combined with some antidepressants.
